Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email [email protected]. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
•Life expectancy at least 3 months
•Diagnosis of a solid tumor which is unresectable in which no approved effective therapy exists or for subjects who are intolerable to such therapy. The initial enrollment will focus on non-small cell lung, gastric/esophageal adenocarcinoma, soft tissue sarcoma, transitional cell carcinoma, and pancreatic cancer including ampulla of Vater tumors
•Adequate tumor sample
•Adequate recovery (baseline or Grade 1) from recent therapy. At least 1 week must have elapsed from the time of a minor surgery, and at least 8 weeks for major surgery or radiation therapy

•Subjects with known brain metastasis.
•Medical History and Concurrent Diseases:
•History of thrombo-embolic disease within the last six months requiring therapeutic anticoagulation
•Subjects with history of poor wound healing or non healing ulcers
•Uncontrolled or significant cardiovascular disease
•Allergies and Adverse Drug Reactions:
•History of allergy to brivanib its drug class, or related compounds
•Prohibited Treatments and/or Therapies:
•Exposure to any investigational drug within 4 weeks of enrollment
•Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiotherapy, standard or investigational. Subjects may continue to receive hormone replacement therapy
•Prior exposure to brivanib

Related studies

NCT06498648 · Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, and more

NCT06422806 · Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, and more

NCT05482568 · Advanced Non-small Cell Lung Cancer

NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more

NCT07001618 · NSCLC (Advanced Non-small Cell Lung Cancer)

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types